RESUMEN
BACKGROUND: Medication nonadherence is associated with worse outcomes in patients with atherosclerotic cardiovascular disease (ASCVD), a group who requires long-term therapy for secondary prevention. It is important to understand to what extent drug costs, which are potentially actionable factors, contribute to medication nonadherence. METHODS: In a nationally representative survey of US adults in the National Health Interview Survey (2013-2017), we identified individuals ≥18 years with a reported history of ASCVD. Participants were considered to have experienced cost-related nonadherence (CRN) if in the preceding 12 months they reported skipping doses to save money, taking less medication to save money, or delaying filling a prescription to save money. We used survey analysis to obtain national estimates. RESULTS: Of the 14 279 surveyed individuals with ASCVD, a weighted 12.6% (or 2.2 million [95% CI, 2.1-2.4]) experienced CRN, including 8.6% or 1.5 million missing doses, 8.8% or 1.6 million taking lower than prescribed doses, and 10.5% or 1.9 million intentionally delaying a medication fill to save costs. Age <65 years, female sex, low family income, lack of health insurance, and high comorbidity burden were independently associated with CRN, with >1 in 5 reporting CRN in these subgroups. Survey respondents with CRN compared with those without CRN had 10.8-fold higher odds of requesting low-cost medications and 8.9-fold higher odds of using alternative, nonprescription, therapies. CONCLUSIONS: One in 8 patients with ASCVD reports nonadherence to medications because of cost. The removal of financial barriers to accessing medications, particularly among vulnerable patient groups, may help improve adherence to essential therapy to reduce ASCVD morbidity and mortality.
Asunto(s)
Aterosclerosis/tratamiento farmacológico , Aterosclerosis/economía , Cumplimiento de la Medicación/psicología , Honorarios por Prescripción de Medicamentos/tendencias , Encuestas y Cuestionarios , Adolescente , Adulto , Anciano , Aterosclerosis/epidemiología , Femenino , Humanos , Masculino , Persona de Mediana Edad , Distribución Aleatoria , Estados Unidos/epidemiología , Adulto JovenRESUMEN
INTRODUCTION: Novel oral oncolytic agents have become the standard of care and first-line therapies for many malignancies. However, issues impacting access to these drugs are not well explored. As part of a quality improvement project in a large tertiary academic institution, we aim to identify potential barriers that delay treatment for patients who are prescribed novel oral oncolytics. METHODS: This was a retrospective review of adults who were newly prescribed a novel oral oncolytic for Food and Drug Administration-approved indications at a single tertiary care center. Patients were identified via electronic prescription data (e-Scribe). Demographics, insurance information, and prescription dates were extracted from the electronic medical record and pharmacy claims data. Statistical analyses were performed to determine whether time-to-receipt was associated with insurance category, pharmacy transfers, cost assistance, and drug prescribed. RESULTS: Of the 270 successfully filled prescriptions, the mean time-to-receipt was 7.3 ± 10.3 days (range: 0-109 days). Patients with Medicare experienced longer time-to-receipt (9.1 ± 13.1 days) compared to patients with commercial insurance (4.4 ± 3.3). Uninsured patients experienced the longest time-to-receipt (15.7 ± 7.8 days) overall. Pharmacy transfers and cost assistance programs were also significantly associated with longer time-to-receipt. Ten prescriptions remained unfilled 90 days after the study period and were considered abandoned. CONCLUSION: Insurance has a significant effect on the time-to-receipt of newly prescribed novel oral oncolytics. Pharmacy transfers and applying for cost assistance are also associated with longer wait times for patients. Our retrospective analysis identifies areas of improvement for future interventions to reduce wait times for patients receiving novel oral oncolytics.
Asunto(s)
Antineoplásicos/administración & dosificación , Neoplasias/tratamiento farmacológico , Servicios Farmacéuticos/normas , Honorarios por Prescripción de Medicamentos/normas , Mejoramiento de la Calidad/normas , Administración Oral , Adulto , Anciano , Anciano de 80 o más Años , Antineoplásicos/economía , Prescripciones de Medicamentos/economía , Prescripciones de Medicamentos/normas , Femenino , Humanos , Masculino , Medicare/economía , Medicare/normas , Medicare/tendencias , Persona de Mediana Edad , Neoplasias/economía , Neoplasias/epidemiología , Servicios Farmacéuticos/economía , Servicios Farmacéuticos/tendencias , Honorarios por Prescripción de Medicamentos/tendencias , Estudios Retrospectivos , Tiempo de Tratamiento , Estados Unidos/epidemiologíaAsunto(s)
Antineoplásicos/economía , Ahorro de Costo , Medicamentos Genéricos/economía , Gastos en Salud/tendencias , Mesilato de Imatinib/economía , Medicare Part D/economía , Honorarios por Prescripción de Medicamentos/tendencias , Anciano , Reforma de la Atención de Salud/legislación & jurisprudencia , Gastos en Salud/legislación & jurisprudencia , Humanos , Honorarios por Prescripción de Medicamentos/legislación & jurisprudencia , Estados UnidosRESUMEN
Sanofi's commitment to limit prices to the rise in the National Health Expenditure Data Accounts--estimated to be 5.6% annually from 2016 to 2025--is not enough, experts said.
Asunto(s)
Costos de los Medicamentos/tendencias , Industria Farmacéutica/economía , Preparaciones Farmacéuticas/economía , Honorarios por Prescripción de Medicamentos/tendencias , Humanos , Estados UnidosAsunto(s)
Sobredosis de Droga/tratamiento farmacológico , Naloxona/economía , Antagonistas de Narcóticos/economía , Honorarios por Prescripción de Medicamentos/tendencias , Analgésicos Opioides/envenenamiento , Costos de los Medicamentos , Sobredosis de Droga/mortalidad , Heroína/envenenamiento , Humanos , Legislación de Medicamentos , Naloxona/administración & dosificación , Antagonistas de Narcóticos/administración & dosificación , Gobierno Estatal , Estados UnidosAsunto(s)
Costos de los Medicamentos/legislación & jurisprudencia , Regulación Gubernamental , Seguro de Servicios Farmacéuticos/legislación & jurisprudencia , Medicamentos bajo Prescripción/economía , Honorarios por Prescripción de Medicamentos/legislación & jurisprudencia , Gobierno Estatal , Costos y Análisis de Costo/legislación & jurisprudencia , Costos de los Medicamentos/tendencias , Industria Farmacéutica/economía , Industria Farmacéutica/legislación & jurisprudencia , Control de Medicamentos y Narcóticos/economía , Control de Medicamentos y Narcóticos/legislación & jurisprudencia , Gobierno Federal , Planes de Asistencia Médica para Empleados/economía , Planes de Asistencia Médica para Empleados/organización & administración , Seguro de Servicios Farmacéuticos/economía , Honorarios por Prescripción de Medicamentos/tendencias , Estados UnidosRESUMEN
This paper explores price differences in the European Union (EU) pharmaceutical market, the EU's fifth largest industry. With the aim of enhancing quality of life along with industry competitiveness and R&D capability, many EU directives have been adopted to achieve a single EU-wide pharmaceutical market. Using annual 1994-2003 data on prices of molecules that treat cardiovascular disease, we examine whether drug price dispersion has indeed decreased across five EU countries. Hedonic regressions show that over time, cross-country price differences between Germany and three of the four other EU sample countries, France, Italy and Spain, have declined, with relative prices in all three as well as the fourth country, UK, rising during the period. We interpret this as evidence that the EU has come closer to achieving a single pharmaceutical market in response to increasing European Commission coordination efforts.
Asunto(s)
Fármacos Cardiovasculares/economía , Industria Farmacéutica/economía , Unión Europea/economía , Preparaciones Farmacéuticas/economía , Fármacos Cardiovasculares/uso terapéutico , Enfermedades Cardiovasculares/tratamiento farmacológico , Enfermedades Cardiovasculares/economía , Comparación Transcultural , Industria Farmacéutica/organización & administración , Industria Farmacéutica/tendencias , Sustitución de Medicamentos/economía , Medicamentos Genéricos/economía , Competencia Económica , Francia , Alemania , Humanos , Italia , Modelos Económicos , Honorarios por Prescripción de Medicamentos/tendencias , España , Reino UnidoAsunto(s)
Amilasas/economía , Aprobación de Drogas/legislación & jurisprudencia , Lipasa/economía , Péptido Hidrolasas/economía , Honorarios por Prescripción de Medicamentos/tendencias , United States Food and Drug Administration/legislación & jurisprudencia , Aprobación de Drogas/economía , Combinación de Medicamentos , Accesibilidad a los Servicios de Salud/economía , Honorarios por Prescripción de Medicamentos/estadística & datos numéricos , Estados UnidosRESUMEN
OBJECTIVE: Determine the impact of the phased reduction of the prescription charge in Wales on prescriptions for non-sedating antihistamines. METHOD: Prescription items for non-sedating antihistamines dispensed in 22 Local Health Boards (LHBs) in Wales and 15 Primary Care Trusts in the South East of England were analysed between October 2001 and September 2006. RESULTS: There was an increase in percent change (median (interquartile range [IQR])) in prescription items for non-sedating antihistamines dispensed in Wales in the 24 months after the first reduction of the prescription charge in October 2004 compared to the 24 months prior to this (13.7 [10.9-17.1] vs. 7.3 [5.0-10.7], p<0.001). In the South East of England there was no change over the same periods (4.4 [3.4-7.5] vs. 4.5 [0.8-7.9], p=0.73). In the five least deprived LHBs the percent change in prescriptions for non-sedating antihistamines increased in the 24 months after the reduction of the prescription charge compared to the previous 24 months (14.3 [11.5-19.4] vs. 9.0 [9.1-13.5], p=0.04). In contrast there was no change over the two periods in the five most deprived LHBs (13.1 [10.9-17.5] vs. 9.5 [2.9-10.4], p=0.08]. CONCLUSIONS: The phased reduction of the prescription charge in Wales coincided with an increase in the number of non-sedating antihistamines dispensed in Wales. This was only evident in the least deprived LHBs.
Asunto(s)
Revisión de la Utilización de Medicamentos , Antagonistas de los Receptores Histamínicos H1 no Sedantes/economía , Pautas de la Práctica en Medicina , Honorarios por Prescripción de Medicamentos/tendencias , Atención Primaria de Salud/estadística & datos numéricos , Seguro de Costos Compartidos , Estudios Transversales , Inglaterra , Disparidades en Atención de Salud , Antagonistas de los Receptores Histamínicos H1 no Sedantes/uso terapéutico , Humanos , Política , Honorarios por Prescripción de Medicamentos/legislación & jurisprudencia , Atención Primaria de Salud/economía , Medicina Estatal/economía , Medicina Estatal/legislación & jurisprudencia , GalesAsunto(s)
Costos de los Medicamentos/estadística & datos numéricos , Producción de Medicamentos sin Interés Comercial/economía , Honorarios por Prescripción de Medicamentos/estadística & datos numéricos , Productos Biológicos/economía , Productos Biológicos/uso terapéutico , Costos y Análisis de Costo , Aprobación de Drogas/estadística & datos numéricos , Costos de los Medicamentos/tendencias , Humanos , Reembolso de Seguro de Salud , Producción de Medicamentos sin Interés Comercial/estadística & datos numéricos , Honorarios por Prescripción de Medicamentos/tendencias , Estados Unidos , United States Food and Drug AdministrationAsunto(s)
Quimioprevención/economía , Seguro de Servicios Farmacéuticos/economía , Cumplimiento de la Medicación/estadística & datos numéricos , Quimioprevención/tendencias , Seguro de Costos Compartidos/economía , Seguro de Costos Compartidos/tendencias , Humanos , Seguro de Servicios Farmacéuticos/tendencias , Patient Protection and Affordable Care Act/economía , Honorarios por Prescripción de Medicamentos/tendencias , Estados UnidosRESUMEN
BACKGROUND: Despite their benefits, the rapid development of new cancer treatments has been a significant driver of increasing health care expenditures in the face of limited health care budgets. In this study, we analyzed the prescribing trends for anticancer drugs from 2010 through 2016 in Japan and sought to identify unique trends that could provide a basis for future medical economic research aiming to develop more efficacious and cost-effective cancer therapies. METHODS: We used publicly available marketing data for anticancer drugs in Japan for 2010-2016. The drugs selected for this research were categorized according to the Anatomical Therapeutic Chemical Classification System. We investigated the overall anticancer drug market size, the number of anticancer drugs, the top 30 selling anticancer categories, sales and prescription volumes, and changes in sales and prescription volumes between 2010 and 2016 in the country. RESULTS: The anticancer agent market expanded each year from 2010 to 2016, with sales exceeding 1 trillion yen in 2015. The proportion of molecular targeted drugs (antineoplastic mAbs and protein kinase inhibitors) among the top 30 selling anticancer categories has continued to increase, and both the sales and prescription volumes of these drugs exceeded those of drugs in other categories, suggesting that these treatments play a dominant role in cancer pharmacotherapy. CONCLUSION: The availability and increasing use of innovative but more expensive targeted therapies were major drivers of increases in pharmaceutical expenditures for cancer treatment in Japan. Therefore, the effective use of genetic testing can mitigate these rising costs.
Asunto(s)
Antineoplásicos/economía , Prescripciones de Medicamentos/estadística & datos numéricos , Neoplasias/tratamiento farmacológico , Antineoplásicos/clasificación , Antineoplásicos Inmunológicos/economía , Desarrollo de Medicamentos/economía , Desarrollo de Medicamentos/tendencias , Prescripciones de Medicamentos/economía , Gastos en Salud/tendencias , Humanos , Japón , Neoplasias/economía , Honorarios por Prescripción de Medicamentos/tendencias , Inhibidores de Proteínas Quinasas/economíaRESUMEN
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA) provides a prescription drug benefit for Medicare-eligible seniors that includes access to medication therapy management services (MTMS) through pharmacists. We theorize that local community pharmacy market competition affects the decision of individual community pharmacies to provide MTMS. Our model suggests that MTMS services are more apt to be supplied in markets at the extremes of community pharmacy concentration (very low and very high). We found that local community pharmacy competition affected the service choices made by the pharmacy decision-makers willing to provide MTMS in a manner consistent with our theory. As a result, patient access to MTMS services depends on both (1) patient access to pharmacies willing to provide MTMS and (2) the level of local community pharmacy competition.
Asunto(s)
Servicios Comunitarios de Farmacia/economía , Utilización de Medicamentos/economía , Competencia Económica/estadística & datos numéricos , Seguro de Servicios Farmacéuticos/estadística & datos numéricos , Medicare/estadística & datos numéricos , Farmacias/economía , Anciano , Actitud del Personal de Salud , Servicios Comunitarios de Farmacia/provisión & distribución , Toma de Decisiones en la Organización , Accesibilidad a los Servicios de Salud , Humanos , Modelos Logísticos , Medicare/organización & administración , Modelos Econométricos , Propiedad/economía , Farmacias/provisión & distribución , Honorarios por Prescripción de Medicamentos/tendencias , Estados UnidosRESUMEN
Purpose The high cost of oncology drugs threatens the affordability of cancer care. Previous research identified drivers of price growth of targeted oral anticancer medications (TOAMs) in private insurance plans and projected the impact of closing the coverage gap in Medicare Part D in 2020. This study examined trends in TOAM prices and patient out-of-pocket (OOP) payments in Medicare Part D and estimated the actual effects on patient OOP payments of partial filling of the coverage gap by 2012. Methods Using SEER linked to Medicare Part D, 2007 to 2012, we identified patients who take TOAMs via National Drug Codes in Part D claims. We calculated total drug costs (prices) and OOP payments per patient per month and compared their rates of inflation with general health care prices. Results The study cohort included 42,111 patients who received TOAMs between 2007 and 2012. Although the general prescription drug consumer price index grew at 3% per year over 2007 to 2012, mean TOAM prices increased by nearly 12% per year, reaching $7,719 per patient per month in 2012. Prices increased over time for newly and previously launched TOAMs. Mean patient OOP payments dropped by 4% per year over the study period, with a 40% drop among patients with a high financial burden in 2011, when the coverage gap began to close. Conclusion Rising TOAM prices threaten the financial relief patients have begun to experience under closure of the coverage gap in Medicare Part D. Policymakers should explore methods of harnessing the surge of novel TOAMs to increase price competition for Medicare beneficiaries.
Asunto(s)
Antineoplásicos/economía , Costo de Enfermedad , Medicare Part D , Terapia Molecular Dirigida/economía , Neoplasias/tratamiento farmacológico , Neoplasias/economía , Honorarios por Prescripción de Medicamentos/estadística & datos numéricos , Administración Oral , Anciano , Anciano de 80 o más Años , Antineoplásicos/administración & dosificación , Comercio/tendencias , Femenino , Humanos , Masculino , Persona de Mediana Edad , Honorarios por Prescripción de Medicamentos/tendencias , Estados UnidosAsunto(s)
Industria Farmacéutica/economía , Medicamentos Genéricos/economía , Medicamentos bajo Prescripción/economía , Seguro de Costos Compartidos , Costos de los Medicamentos/tendencias , Formularios Farmacéuticos como Asunto , Humanos , Motivación , Honorarios por Prescripción de Medicamentos/tendenciasAsunto(s)
Servicios Comunitarios de Farmacia/economía , Costos de los Medicamentos/tendencias , Industria Farmacéutica/economía , Seguro de Servicios Farmacéuticos/economía , Honorarios por Prescripción de Medicamentos/tendencias , Actitud del Personal de Salud , Industria Farmacéutica/organización & administración , Competencia Económica/normas , Competencia Económica/tendencias , Humanos , Estados UnidosRESUMEN
OBJECTIVES: In the European context of falling reimbursement rates for some osteoarthritis (OA) treatments, we performed a study to determine whether the cost covered by patients influenced the decisions of their physicians' prescriptions for medication. METHODS: The study involved 106 general practitioners (GPs) and 82 rheumatologists. Preferences were elicited using a discrete choice experiment. Scenarios were generated including seven treatment attributes with associated different levels: pain relief, improvement in function, retardation of joint degradation, risk of moderate side effects, risk of serious side effects, cost borne by the patient and degree of patient acceptance of the treatment. KEY FINDINGS: OA treatment choices were significantly influenced by pain relief (ß = 1.1533, P < 0.0001 for GPs and ß = 0.5043, P = 0.0024 for rheumatologists), improvement in function (ß = 1.2140 for GPs and ß = 0.7192 for rheumatologists, P < 0.0001), annual cost to the patient (ß = -0.0054 for GPs and ß = -0.0038 for rheumatologists, P < 0.0001) and serious side effects (ß = -0.5524 for GPs and ß = -0.4268 for rheumatologists, P < 0.0001). The risk of moderate side effects only had an impact on GP decision making (ß = 0.0282, P = 0.0028). All physicians were willing to make patients bear an extra annual cost of: (1) 225 among GPs and 189 among rheumatologists so that they could benefit from one unit improvement in function; and (2) 214 among GPs and 133 among rheumatologists so that they could benefit from a one unit improvement in pain relief. CONCLUSION: When making decisions about which treatment to prescribe, physicians take into account the cost to patients. Changes in reimbursement rates for some OA treatments may lead to changes in prescribing practices.
Asunto(s)
Conducta de Elección , Médicos Generales/psicología , Osteoartritis/tratamiento farmacológico , Honorarios por Prescripción de Medicamentos/tendencias , Reumatólogos/psicología , Adulto , Anciano , Prescripciones de Medicamentos/economía , Europa (Continente) , Femenino , Humanos , Reembolso de Seguro de Salud/tendencias , Masculino , Persona de Mediana Edad , Osteoartritis/economía , Prioridad del Paciente , Pautas de la Práctica en Medicina , Encuestas y Cuestionarios , Resultado del TratamientoRESUMEN
BACKGROUND: Sunitinib and pazopanib are among the most prescribed targeted therapies for the systemic management of advanced renal cell carcinoma (RCC), but published cost comparisons between the 2 agents are few and limited by methodological and population differences. Also, sunitinib is administered on a 4-week on/2-week off cycle, and pazopanib is taken continuously. Thus, appropriate use and cost comparisons between the 2 drugs require methodological approaches to account for these differences. One way to accomplish this is to substitute expected for observed days supply. Recognizing the effects of nonrepresentative days supply values is important for assessing real-world treatment patterns and costs. OBJECTIVES: To (a) characterize demographic and clinical characteristics among patients with RCC newly initiating sunitinib or pazopanib, using a large administrative claims dataset; (b) characterize treatment patterns, persistence, and costs for each treatment group; and (c) assess the effect on treatment patterns and costs for sunitinib by substituting 42 days for prescriptions with 28- or 30-day supplies to account for sunitinib's 4-week on/2-week off dosing schedule. METHODS: This was a retrospective cohort study using health care claims data from the Truven MarketScan Research Databases, which include enrollment information and medical and pharmacy claims. Baseline patient demographic and clinical characteristics and treatment patterns (continuation, discontinuation, switching, or interruption; days supply; and persistence) were compared. Health care costs were calculated as mean daily index medication costs and as total, medical, and medication (all-cause and RCC-related) costs over the 12 months post-index period. Inclusion criteria were continuous health plan enrollment between 6 months pre-index and 12 months post-index; no RCC medications 6 months pre-index; ≥ 2 RCC diagnoses within ±180 days of index; and age ≥ 20 years. For demographic and clinical characteristics, treatment patterns, and costs, means (± standard deviations) for continuous data and relative frequencies for categorical data were reported. Chi-square tests or Student t-tests were used to evaluate differences other than costs. A generalized linear model with gamma distribution and log link was used for evaluating costs, controlling for patient demographic and pre-index clinical characteristics, persistence days, and index medication. All statistical tests were 2-tailed with significance set at P < 0.05 for all comparisons except for interactions with significance set at P < 0.10. The effects of substituting 42 days supply for sunitinib prescription records with 28 or 30 days supply were determined. RESULTS: In total, 609 (15.1% of the sunitinib overall sample) sunitinib patients and 183 (8.3% of the pazopanib overall sample) pazopanib patients were included. Demographic and clinical characteristics were similar for each treatment cohort. The persistence periods and number of prescriptions filled were also similar. Without substitution, significant differences were observed between treatment groups in patterns of index medication use (overall P = 0.0409), with fewer patients taking sunitinib continuing treatment than patients taking pazopanib. However, with substitution, treatment patterns differed significantly (overall P = 0.0026), but with more sunitinib patients than pazopanib patients continuing treatment. Without substitution, unadjusted daily mean index medication costs were significantly different for sunitinib ($216) versus pazopanib ($177, P < 0.0001). Substitution of sunitinib days supply eliminated the significant differences in daily index medication costs between treatment groups. The 1-year RCC-related and all-cause medication, medical, and total unadjusted costs were not significantly different between treatment groups, and substitution had no effect on these costs. After adjustment for possible confounding factors, these cost results were similar to those found with unadjusted analyses. CONCLUSIONS: In this study, patients with RCC who were initiating sunitinib and pazopanib had similar demographic and clinical characteristics and drug persistence patterns. The effect of substituting days supply values was demonstrated as an approach to considering differences in dosing cycles. Substitution significantly reduced sunitinib mean daily index medication costs and eliminated or reversed the direction of significant differences in costs between drugs during the persistence period. No significant differences were observed in unadjusted or adjusted 1-year costs. DISCLOSURES: This study was funded and conducted fully by Pfizer. All authors are employees of Pfizer. This work was presented in part as posters at the 2015 Genitourinary Cancers Symposium, of the American Society of Clinical Oncology; Rosen Shingle Creek, Orlando, FL; February 26-28, 2015, and the 20th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research; Philadelphia, PA; May 16-20, 2015. All authors contributed to study concept and design and to data interpretation. Mardekian was primarily responsible for data collection, along with Harnett. MacLean and Harnett worked on the manuscript, which was revised by MacLean and Mardekian.